ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis
Renal Cell Carcinoma
Colorectal Cancer
Carcinoma

Melanoma trials near Montréal, QC, CAN:

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma...

Enrolling
Advanced Melanoma
Drug: Tebentafusp with Pembrolizumab
Drug: Tebentafusp

Phase 3

Immunocore
Immunocore

Montreal, Quebec, Canada and 81 other locations

the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...

Active, not recruiting
Melanoma
Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib
Drug: Encorafenib and Binimetinib

Phase 3

Pierre Fabre
Pierre Fabre

Montréal, Quebec, Canada and 154 other locations

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Montréal, Quebec, Canada and 71 other locations

and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...

Active, not recruiting
Advanced or Metastatic NRAS-mutant Melanoma
Drug: Trametinib
Drug: Naporafenib

Phase 3

Erasca

Montreal, Quebec, Canada and 58 other locations

The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the com...

Enrolling
Melanoma
Drug: fianlimab
Drug: cemiplimab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Montreal, Quebec, Canada and 107 other locations

antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...

Active, not recruiting
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Montreal, Quebec, Canada and 67 other locations

use the immune system to recognize and kill cancer cells. The study is focused on participants with a type of skin cancer known as melanoma...

Active, not recruiting
Melanoma
Drug: Placebo
Drug: cemiplimab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Montreal, Quebec, Canada and 103 other locations

be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on either pembrolizumab o...

Active, not recruiting
Stage III/IV Melanoma
Biological: Pembrolizumab
Biological: tavokinogene telseplasmid

Phase 2

OncoSec Medical

Montréal, Quebec, Canada and 32 other locations

and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...

Active, not recruiting
Melanoma
Other: Placebo
Biological: Nivolumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Montreal, Quebec, Canada and 130 other locations

study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma...

Active, not recruiting
Melanoma
Biological: Nivolumab
Biological: Relatlimab

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Montreal, Quebec, Canada and 126 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems